Recent FDA Updates: December 2025 – January 2026
A summary of FDA guidance documents, technical amendments and policy clarifications released between December 2025 and January 2026.
Read more →Research compliance resources from HRP Consulting Group: regulatory summaries, comparison tables, sample guidelines and presentations.
A summary of FDA guidance documents, technical amendments and policy clarifications released between December 2025 and January 2026.
Read more →HRP’s summary of the unified USDA General Terms & Conditions, prepared for research administration and compliance teams.
Read more →Summary and sample information sheet on the IRS reporting threshold for research participant compensation, which rose from $600 to $2,000 in 2026.
Read more →This presentation reviews what "vulnerability" means when conducting human-subjects research. "Vulnerability" should be understood broadly and contextually — beyond just legally defined groups — and researchers must proactively identify and mitigate a variety of risks (e.g. power imbalances, coercion, confidentiality,…
Read more →The attached document provides a summary of the new rules from the U.S. Department of Justice (DOJ) and National Institutes of Health (NIH) that tighten controls on access to U.S. “bulk sensitive personal data” and government-related data — forbidding or…
Read more →Sample IRB guidelines for investigators whose human subjects research may be subject to a stop work or pause work directive from a federal funding agency.
Read more →This document provides a detailed side-by-side comparison of the regulations under Common Rule and current (and proposed) U.S. Food and Drug Administration (FDA) regulations (21 CFR 50/56 etc.), showing how FDA’s human-subjects-research and IRB requirements could be harmonized — or…
Read more →The document outlines proposed revisions (2022–2024) by U.S. Food and Drug Administration (FDA) to its human-subjects and IRB regulations (21 CFR 50, 56, and 812), aiming to harmonize FDA rules with the revised Common Rule — including updates to informed-consent…
Read more →A one page summary to clarify guidance on determining when CDS software is excluded from the definition of a “medical device” under section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Only software functions that meet all four specified…
Read more →Summarizes the changes to NIH Guidance for IACUC programs that are USDA registered – providing IACUCs greater flexibility in how they conduct semiannual program reviews and inspections.Download
Read more →